TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01107522
Drug: CTO, Temodar®, Radiation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration of CTO daily for 28 day cycles; starting dose of CTO = 219 mg/m2 Temodar® administered orally at a dose of 75 mg/m2 daily during radiation therapy, then at 150mg/m2 for Days 1-5 of Cycle 1, and then up to 200 mg/m2 Days 1-5 of subsequent cycles Radiation: 3-dimensional conformal radiation therapy or, Radiation: intensity-modulated radiation therapy
Study: NCT02183324
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02752243
Drug: CIK-Cells
Normalized name: Testone CIK KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: IL-15 activated CIK cells individually generated from PB mononuclear cells of the original stem cell donors.
Study: NCT01285362
Drug: Placebo Supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group B will receive corn oil in the capsules at the same dose as Group A. The corn oil capsules will appear identical in size and color to the fish oil capsules.
Study: NCT01118741
Drug: Disulfiram
Normalized name: Disulfiram
DrugBank: Disulfiram (DB00822)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cohort 1: 250mg PO daily for 28 days Cohort 2: 500mg PO daily for 28 days
Study: NCT05214690
Drug: DW1809-T2
Approvals — FDA: no, EMA: no, PMDA: no
Description: pelubiprofen 25mg
Study: NCT05214690
Drug: DW1809-1
Approvals — FDA: no, EMA: no, PMDA: no
Description: pelubiprofen 30mg (PELUBI tab.)
Study: NCT01420068
Drug: SPP100
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03004638
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received 3 doses of placebo matching with MEDI6012 intravenously (IV) on Days 1, 8, and 15.
Study: NCT03004638
Drug: Placebo IV Push
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received 3 doses of placebo matching with MEDI6012 by IV push. A loading dose on Day 1 and maintenance doses on Days 3 and 10.
Study: NCT01139775
Drug: LY2603618
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered intravenously as a continuous 1-hour infusion
Study: NCT00365794
Drug: Topical testosterone gel 10 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testosterone gel therapy for 20 weeks
Study: NCT02707484
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients were randomly assigned to receive a 120-days course of placebo (Pharmaceutical Co., Ltd. of ChangZhou, China).
Study: NCT02631642
Drug: HMPL-689
Approvals — FDA: no, EMA: no, PMDA: no
Description: selective PI3Kδ inhibitor
Study: NCT02631642
Drug: HMPL-689 placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo of HMPL-689
Study: NCT02940756
Drug: artemether-lumefantrine
Normalized name: artemether-lumefantrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets containing 20 mg of Artemether and 120 mg of Lumefantrine. Each dose to be taken with high-fat food or drinks (for example milk).~One tablet twice daily for children weighing 5 to \<15 kg, two tablets twice daily for those weighing 15 to \<25 kg and three tablets twice daily for those weighing 25 to \< 35 kg, for three days.
Study: NCT01061112
Drug: Flurbiprofen Control - Flurbiprofen Only
Normalized name: Flurbiprofen
DrugBank: Flurbiprofen (DB00712)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A single 50 mg flurbiprofen dose taken at the start of the study period. No other drugs administered during this study period.
Study: NCT01061112
Drug: Flurbiprofen Inhibition - Flurbiprofen & Fluconazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single 50 mg flurbiprofen dose taken at the start of the study period. 400 mg fluconazole taken every morning starting a week before the start of the study period and continuing throughout the study period.
Study: NCT01061112
Drug: Ketoprofen Control - Ketoprofen Only
Normalized name: Ketoprofen
DrugBank: Ketoprofen (DB01009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A single 75 mg ketoprofen dose taken at the start of the study period. No other drugs administered during this study period.
Study: NCT01061112
Drug: Ketoprofen Inhibition - Ketoprofen & Fluconazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single 75 mg ketoprofen dose taken at the start of the study period. 400 mg fluconazole taken every morning starting a week before the start of the study period and continuing throughout the study period.
Study: NCT02473939
Drug: VR942 delivered via a Vectura Dry Powder Inhaler
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02473939
Drug: Placebo delivered via a Vectura Dry Powder Inhaler
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00020787
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dose: 1000mg/m2/day Route: 24-hour continuous infusion in 0.9% NaCl over 5 days Schedule: Day 1 to Day 5 (5-day infusion) and then every 4 weeks
Study: NCT02545959
Drug: methylprednisolone IV
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: blood infusion of methylprednisolone IV (120mg)
Study: NCT04486937
Drug: S410914 tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: S410914 tablet
Study: NCT01624571
Drug: LD02GIFRO
Approvals — FDA: no, EMA: no, PMDA: no
Description: comparison of different dosages of drug
Study: NCT04119297
Drug: Heparinoids Topical Cream
Normalized name: heparinoids Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Heparinoid cream was applied to the periorbital area once at 3rd and 9th hours following craniotomy, and 4 times daily in the following 3 days.~* Periorbital edema, upper and lower eyelid ecchymosis of the patients were evaluated on the 3rd and 9th hours after craniotomy, and on the 1st, 2nd and 3rd days (twice daily) using the Kara \& Gokalan's Scale
Study: NCT00569972
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched oral placebo for weeks 2-7.
Study: NCT01099618
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The study subject will receive a placebo tablet once a day as long as the patient maintains near-normoglycemic remission (BG \< 130mg/dL and A1c \<7%) during the 3-year follow-up period.
Study: NCT00966992
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT04124731
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1. Pemetrexed combined with platinum regimen (non-squamous cell carcinoma): pemetrexed 500mg/m2, intravenous infusion on the first day of each cycle, cisplatin 75mg/m2 or carboplatin AUC 5, intravenous infusion on the first day of each cycle, 1 cycle every 3 weeks (Q3W), 4 cycles in total. Patients who did not progress after 4 cycles received maintenance monotherapy with pemetrexide at the same dose as before.~2. Gemcitabine combined with platinum regimen (squamous cell carcinoma): gemcitabine 1250mg/m2, intravenous infusion on day 1 and day 8 of each cycle, cisplatin: 75mg/m2 or carboplatin: AUC 5, intravenous infusion on day 1 of each cycle, 1 cycle every 3 weeks (Q3W), 4-6 cycles in total.
Study: NCT02965573
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02095548
Drug: SM04690, 0.07mg/2mL
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02095548
Drug: SM04690, 0.23mg/2mL
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02095548
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04503148
Drug: Inhaled General Anesthetics
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sevoflurane or desflurane for induction and maintenance of anesthesia
Study: NCT02173691
Drug: Placebo inhalation aerosol
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02173691
Drug: Placebo inhalation powder capsules
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03187301
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo single dose
Study: NCT03922308
Drug: SHP655
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive injection of SHP655.
Study: NCT04291287
Drug: Antithrombotic Agent
Normalized name: ANTITHROMBOTIC AGENTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adenosine diphosphate (ADP) receptor antagonists (or P2Y12 inhibitors) therapy include:~* Clopidogrel (Plavix®)~* Prasugrel (Efient®)~* Ticagrelor (Brilique®)~DOACs therapy include:~* Apixaban (Eliquis®)~* Dabigatran (Pradaxa®)~* Edoxaban (Lixiana®)~* Rivaroxaban (Xarelto®).~Oral anticoagulant therapy (OAT) include:~* Warfarin (Counmadin®)~* Acenocumarol (Sintrom®)
Study: NCT02158585
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo will match the lamotrigine dosage, frequency and duration.
Study: NCT04089631
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 6 months capecitabine, in combination with oxaliplatin 3 to 6 months capecitabine
Study: NCT01072773
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 300 mg/m\^2, orally, on days 1, 8, 15 \& 22 every 28 days.
Study: NCT02809729
Drug: sterile saline
Normalized name: Aqua Care Sterile Saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% saline sterile by endovenous, once, at the moment of anesthetic induction
Study: NCT04287660
Drug: clarithromycin, lenalidomide, dexamethasone and autologous BCMA-directed CAR T-cells
Approvals — FDA: no, EMA: no, PMDA: no
Description: * clarithromycin: 500mg, PO, twice daily, on days 1\~21 for a 28-day cycle.~* lenalidomide: 25mg, PO, on days 1\~21 for a 28-day cycle. dexamethasone: 40mg, PO on days 1,8,15 and 22 for a 28-day cycle. BCMA CAR T cell: (2-3)×10E7/kg, intravenously infusion.~* Doses should be adjusted according to renal function.
Study: NCT04303689
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: patients with essential hypertension are randomized to receive either 3 weeks of placebo-treatment
Study: NCT01047059
Drug: Fluoro-L-thymidine
Normalized name: L-thymidine
DrugBank: Telbivudine (DB01265)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: FLT-PET tracer for imaging
Study: NCT01965756
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01256450
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: buccal soluble film; applied to the buccal mucosa twice daily
Study: NCT00513981
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00513981
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT05859919
Drug: The drug Rutan 0.1.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active ingredient: (3,6-bis-O-galloyl-1,2,4-tri-O-galloyl-β-D-glucose). Active substance: Rutan 0.1 100mg. Excipients: potato starch, calcium stearate, lactulose.
Study: NCT02645240
Drug: Heparin injection
Normalized name: heparin Injection
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous heparin injection in patients with acute mesenteric ischemia and evaluating their response within 24 hours
Study: NCT02042989
Drug: MLN9708
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose Escalation Phase - Starting Dose of MLN9708: 3 mg by mouth on day 1, 8 and 15.~Dose Expansion Phase Starting Dose of MLN9708: Maximum tolerated dose from Dose Escalation Phase.
Study: NCT02108548
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral
Study: NCT02108548
Drug: naproxen
Normalized name: Naproxen
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral
Study: NCT02364830
Drug: Colpermin®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colpermin® Capsule/Day for 4 Weeks
Study: NCT03751098
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eyewash administered with the Optejet microdose dispenser
Study: NCT03950830
Drug: Disulfiram
Normalized name: Disulfiram
DrugBank: Disulfiram (DB00822)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Disulfiram 400mg daily, continuously
Study: NCT00566241
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT03906617
Drug: Intercostal nerve block and wound infiltration with bupivacaine/epinephrine + dexamethasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intercostal nerve block and wound infiltration with liposomal bupivacaine during robotic lung resection surgery. 42 ml of 0.5% Bupivacaine/epinephrine with 8mg dexamethasone will be used.
Study: NCT04382781
Drug: NO-Immunosuppressive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients not receiving immunosuppressive drugs
Study: NCT04382781
Drug: Immunosuppressive
Normalized name: Immunosuppressive acidic protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients receiving immunosuppressive drugs (overall, and specific drugs)
Study: NCT04382781
Drug: Immunoglubulins
Normalized name: immunoglobulin A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients receiving immunoglubulins
Study: NCT01867125
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lebrikizumab matching placebo will be administered as SC injection every 4 weeks for 52 weeks.
Study: NCT00223041
Drug: Fluvastatin
Normalized name: Fluvastatin
DrugBank: Fluvastatin (DB01095)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Arm A receives fluvastatin Arm b receives no fluvastatin
Study: NCT02137213
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline will be added to oral methadone preparations as placebo.
Study: NCT00529503
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Volume as equivalent to corresponding SGN 40 dose IV. Cycle 1: Days -1, 3, 8, 15. Cycles 2, 3: Days 1, 8, 15.
Study: NCT02531308
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Interferes with DNA replication
Study: NCT02531308
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: anthracycline antitumor antibiotic
Study: NCT04177095
Drug: Immunosuppression reduction
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stepwise reduction in the dose, and ultimate discontinuation of, all non-belatacept immunosuppression (mycophenolate, sirolimus, everolimus, prednisone) guided by monitoring of Allosure and Trugraf results
Study: NCT02211209
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01532856
Drug: Thalidomide, Cyclophosphamide, Dexamethasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thalidomide - 200mg per day, orally, during 9 cycles of 28 days each cycle Cyclophosphamide - 50mg per day, orally, during 9 cycles of 28 days each cycle Dexamethasone - 40mg orally(two pulses the first two cycles in days 1-4 and 15-18 and then a single pulse in each other cycle) during 9 cycles of 28 days.
Study: NCT04009525
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide（50 mg/kg/day,4 days）
Study: NCT04009525
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate
Study: NCT01252095
Drug: PG545
Normalized name: Heparan Sulfate Mimetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: PG545 Lyophilized Powder for Subcutaneous Injection. Patients will be dosed once weekly until they exhibit disease progression, are discontinued for reasons of tolerability, or the study reaches its defined end-point. This study is a dose escalation study with doses of 25 mg to 500 mg planned.
Study: NCT04752852
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 ml normal saline (0.9%) IV, 60 minutes before the induction of anaesthesia
Study: NCT01088763
Drug: gamma-secretase/Notch signalling pathway inhibitor RO4929097
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT01753310
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Up to 2mL
Study: NCT03447925
Drug: Medicinal Plant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medicinal Plant Extract with vaseline cream
Study: NCT03193853
Drug: Tak-228 & Tak-117
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive 4mg oral TAK-228 and 200mg TAK-117 tablets until disease progression.
Study: NCT01537926
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: sugar pill manufactured to minic NAC 600mg capsule
Study: NCT00290953
Drug: SR48692
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00669097
Drug: TKI258
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01636271
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT00941486
Drug: FST-100 Ophthalmic Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: FST-100 (PVP-I 0.4% and dexamethasone 0.1%). A regimen of 2 drops 4 times a day while awake for 5 days.
Study: NCT00941486
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A regimen of 2 drops 4 times a day while awake for 5 days.
Study: NCT00580151
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 dose every 6 hours
Study: NCT01862926
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03139474
Drug: Gonadotropin-Releasing Hormone Analogue
Normalized name: Gonadotropin releasing hormone analogues
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triptorelin at a dose 1 mg per day from the midluteal phase of the cycle preceding the treatment cycle to day 2 of the cycle then 0.5 milligram of triptorelin will be used during the period of stimulation.
Study: NCT03139474
Drug: Gonadotropin releasing hormone antagonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: antagonist group :Multiple dose gonadotrophin-releasing hormone antagonist regimen will be used for ovarian stimulation 0.25 microgram per day cetrorelix will be administered from the 6th day of ovarian stimulation or from the presence of follicle 14 millimeter diameter .We will give them gonadotrophin for 5 days , Triggering by Human Chorionic Gonadotrophin will be administered for each group when size of follicle reach \> 17 millimeter .Oocytes will retrieved by transvaginal ultrasound , 34-36 hours after Human Chorionic Gonadotrophin administration .
Study: NCT00880412
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: In each arm, 2 capsules of study treatment (capsules of EHT0202 40mg and/or placebo) are taken twice a day during breakfast and dinner over a 3-month treatment period. There is non treatment adjustment.
Study: NCT03113812
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00184886
Drug: Methotrexate 15 mg/week for 12 weeks
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00615550
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: vaginal gel, 1.125 Grams once daily, beginning at 19 0/7 to 23 6/7 weeks gestation through 36 6/7 weeks gestation
Study: NCT01731119
Drug: Latuda©
Approvals — FDA: no, EMA: no, PMDA: no
Description: All subjects will be started on 20-40mg of Latuda© at night (suggested intake with food). Subsequently, the dose may be increased as clinically indicated and based on tolerability every 7 days by 20-40mg to a maximum of 160mg per day with food which may be given as a single or twice daily dose depending on participant's preference. The maintenance dose will be determined solely by the clinician in accordance with the best interests of each participant.
Study: NCT01205269
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dry powder for inhalation, single dose
Study: NCT01205269
Drug: AZD8683, 200 mcg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dry powder for inhalation, single dose
Study: NCT02192463
Drug: NVP ER 300 mg (KCR 30%) Slow Release
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02192463
Drug: NVP ER 300 mg (KCR 40%) Slow Release
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02192463
Drug: NVP ER 300 mg (ECR 20%) Fast Release
Normalized name: phentermine hydrochloride Extended Release Oral Tablet [Pro-Fast]
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02192463
Drug: NVP ER 400 mg (KCR 30%) Slow Release
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02192463
Drug: NVP ER 400 mg (KCR 40%) Slow Release
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02192463
Drug: NVP ER 400 mg (ECR 20%) Fast Release
Normalized name: phentermine hydrochloride Extended Release Oral Tablet [Pro-Fast]
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01991743
Drug: Group 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of bupivacaine 2.5 mg.
Study: NCT01991743
Drug: Group 5
Normalized name: Chlamydophila psittaci biogroup 5 Ab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of 5 mg bupivacaine
Study: NCT00987337
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: BID
Study: NCT03830333
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline by IV infusion every 8 hours for 4 to 14 days.
Study: NCT01768377
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl 2 microgram/Kg BW IV
Study: NCT04033354
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT01129427
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: matching tablet~Route of administration: oral
Study: NCT04432766
Drug: BAT2020
Approvals — FDA: no, EMA: no, PMDA: no
Description: After a cohort completes the study on Day 28, data on safety and tolerability for each cohort will be evaluated by the Safety Monitoring Committee (SMC). Administration of the next higher dose to a new dosing cohort will be permitted only if adequate safety and tolerability have been demonstrated. If encouraging clinical benefit is observed at a certain dose level, the study may proceed to a to Part 2 based on emerging data.
Study: NCT01047566
Drug: Beta blocker or calcium antagonist or digoxin
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose increase of beta blocker or calcium antagonist or digoxin
Study: NCT02276248
Drug: GDP chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: gemcitabine (1000mg/m2 intravenously over 30 minutes on days 1 and 8), cisplatin (25mg/m2 intravenously over 60 minutes on days 1-3), and dexamethasone (20mg/d orally on days 1-4 and days 11-14), which was administered every 21 days.
Study: NCT00802048
Drug: Local anesthetic (Ropivacaine)
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local anesthetic infusion
Study: NCT04231617
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo